Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.

Humans COVID-19 Vaccines BCG Vaccine Antibody Formation COVID-19 / prevention & control Vaccination ChAdOx1 nCoV-19 Immunoglobulin G
BCG COVID-19 ChAdOx1-S CoronaVac antibody vaccine

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 24 02 2023
accepted: 12 06 2023
medline: 21 7 2023
pubmed: 19 7 2023
entrez: 19 7 2023
Statut: epublish

Résumé

Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.

Identifiants

DOI: 10.3389/fimmu.2023.1172851 PMID: 37465688 PMC: PMC10352084
pubmed: 37465688
doi: 10.3389/fimmu.2023.1172851
pmc: PMC10352084
doi:

Substances chimiques

sinovac COVID-19 vaccine 0
COVID-19 Vaccines 0
BCG Vaccine 0
ChAdOx1 nCoV-19 B5S3K2V0G8
Immunoglobulin G 0

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1172851

Informations de copyright

Copyright © 2023 Messina, Sperotto, Puga, da Silva, de Oliveira, Moore, Pittet, Jamieson, Dalcolmo, dos Santos, Jardim, Lacerda, Curtis and Croda.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Clin Immunol. 2023 Jan;246:109208
pubmed: 36565972
Tuberculosis (Edinb). 2014 May;94(3):226-37
pubmed: 24572168
Clin Transl Immunology. 2022 Apr 22;11(4):e1387
pubmed: 35573165
Clin Microbiol Infect. 2019 Dec;25(12):1484-1493
pubmed: 30797062
Rev Med Virol. 2022 Jul;32(4):e2313
pubmed: 34755408
Clin Infect Dis. 2022 Aug 24;75(1):e938-e946
pubmed: 35247264
Infect Immun. 2002 Feb;70(2):672-8
pubmed: 11796598
Microbes Infect. 2023 Jan-Feb;25(1-2):105044
pubmed: 36096357
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
NPJ Vaccines. 2021 Nov 30;6(1):143
pubmed: 34848711
Vaccines (Basel). 2023 Jan 04;11(1):
pubmed: 36679966
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Lancet Infect Dis. 2021 Nov;21(11):1590-1597
pubmed: 34237262
BMJ. 2010 Mar 15;340:c671
pubmed: 20231251
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33211672
Sci Adv. 2022 Aug 5;8(31):eabn4002
pubmed: 35930640
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
N Engl J Med. 2022 Dec 15;387(24):2203-2206
pubmed: 36507702
Vaccine. 2022 Feb 11;40(7):1019-1025
pubmed: 35033389
Front Immunol. 2021 Mar 08;12:632478
pubmed: 33763077
Virus Res. 2021 Aug;301:198454
pubmed: 34015363
BMJ Open. 2022 May 24;12(5):e059994
pubmed: 35613792
J Immunol. 2023 Jun 15;210(12):1925-1937
pubmed: 37098890
Vaccines (Basel). 2022 Dec 29;11(1):
pubmed: 36679920
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
J Clin Med. 2023 Feb 01;12(3):
pubmed: 36769802
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
J Innate Immun. 2014;6(2):152-8
pubmed: 24192057
Br J Nurs. 2021 Mar 25;30(6):344-349
pubmed: 33769885
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Expert Rev Vaccines. 2018 Jun;17(6):547-554
pubmed: 29882438
J Med Virol. 2022 May;94(5):2139-2148
pubmed: 35060174
J Infect Dis. 2020 Jun 11;221(12):1999-2009
pubmed: 31990350
Front Immunol. 2022 Jul 28;13:894277
pubmed: 35967368
J Infect Dis. 2018 May 5;217(11):1798-1808
pubmed: 29415180
Int J Infect Dis. 2022 Jan;114:252-260
pubmed: 34800687
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Lancet Microbe. 2022 Apr;3(4):e274-e283
pubmed: 35165669
mBio. 2023 Apr 25;14(2):e0035623
pubmed: 36976004
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Nat Microbiol. 2022 Sep;7(9):1490-1500
pubmed: 35982313
BMJ Open. 2021 Oct 28;11(10):e052101
pubmed: 34711598
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
J Infect Dis. 2019 Aug 30;220(7):1091-1098
pubmed: 31165861
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Vaccines (Basel). 2022 Sep 23;10(10):
pubmed: 36298466
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Pediatr Res. 2016 Nov;80(5):681-685
pubmed: 27429204
Science. 2021 May 21;372(6544):821-826
pubmed: 33853971
Annu Rev Med. 2022 Jan 27;73:17-39
pubmed: 34669432
Nat Rev Immunol. 2016 Jun;16(6):392-400
pubmed: 27157064
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33306484

Auteurs

Nicole L Messina (NL)

Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.

Mariana G Sperotto (MG)

School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.

Marco A M Puga (MAM)

School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.

Patricia V da Silva (PV)

School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.

Roberto D de Oliveira (RD)

State University of Mato Grosso do Sul, Dourados-Mato Grosso do Sul, Brazil.
Federal University of Grande Dourados, Dourados, Brazil.

Cecilia L Moore (CL)

Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, VIC, Australia.

Laure F Pittet (LF)

Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
Infectious Diseases, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia.

Tenaya Jamieson (T)

Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.

Margareth Dalcolmo (M)

Helio Fraga Reference Center, Oswaldo Cruz Foundation Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil.
Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.

Glauce Dos Santos (G)

National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.

Bruno Jardim (B)

Institute of Clinical Research Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

Marcus V G Lacerda (MVG)

Institute of Clinical Research Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

Nigel Curtis (N)

Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
Infectious Diseases, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia.

Julio Croda (J)

School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Yale School of Public Health, New Haven, CT, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antibactériens › Vaccins antituberculeux › Vaccin BCG › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité active › Production d'anticorps › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Vaccin ChAdOx1 nCoV-19 › Impact of vaccine platform and BCG vaccination...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Impact of vaccine platform and BCG vaccination...